Remaining pipeline and cash cushion investor blow as Targacept ends another programme
This article was originally published in Scrip
Executive Summary
After Targacept announced the unsuccessful end of its third clinical development programme this year and said for the second time in 2012 that it would lay off employees, the company - which is focused on therapeutics that selectively target neuronal nicotinic receptors (NNRs) to treat nervous system diseases and disorders - experienced a relatively small 11.1% decline in its stock price on 17 September, given its recent string of failures.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).